Amgen Inc. with ticker code (AMGN) now have 23 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $381.00 and $180.00 calculating the average target price we see $328.50. Given that the stocks previous close was at $329.15 this indicates there is a potential downside of -.2%. The day 50 moving average is $321.30 while the 200 day moving average is $295.26. The market cap for the company is 176.32B. Currently the stock stands at: $328.15 USD
The potential market cap would be $175,976,306,958 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 56.68, revenue per share of $57.66 and a 4.48% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
